Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans

January 31, 2019

Charles Ryan interviews Alicia Morgans on her thoughts about treatment decision making in the metastatic hormone-sensitive prostate cancer (mHSPC) population and changes that are rapidly developing in this area. They review how studies such as CHAARTED, LATITUDE, and STAMPEDE have shaped the current options. The discuss the next sets of data that are expected to further expand treatment options in the near future. We look forward to the first of this new data at the upcoming ASCO GU 2019 meeting from the ARCHES Trial: A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC). Alicia and Chuck establish the foundation for considerations in the future treatments in mHSPC.

Biographies:

Charles J. Ryan, MD, the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. Charles J. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced prostate cancer. Dr. Ryan joined the PCF from the University of Minnesota, Minneapolis, where he served as Director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine. He also served as Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology.

Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.



Related Content:

Small Cells, Big Worries

email news signup